Table 7.
Net patient economic burden associated with cancer in the United States in 2019a
| Site | Patient out-of-pocket costs by phase of care (in millions)b |
Patient time cost (in millions) | Patient economic burden (in millions) | ||||
|---|---|---|---|---|---|---|---|
| Initial | Continuing | End-of-life cancer death | End-of-life other cause of death | Total out-of-pocket costs | |||
| Bladder | $160.3 | $440.9 | $62.4 | $39.1 | $702.6 | $235.4 | $938.0 |
| Breast | $955.4 | $1937.3 | $181.7 | $63.4 | $3137.8 | $1112.2 | $4250.0 |
| Cervix | $63.0 | $82.7 | $17.6 | $8.6 | $172.0 | $82.7 | $254.6 |
| Colorectal | $497.2 | $684.4 | $221.2 | $57.4 | $1460.3 | $440.6 | $1900.9 |
| Hodgkin lymphoma | $77.3 | $153.6 | $9.8 | $6.3 | $247.0 | $70.1 | $317.1 |
| Kidney | $143.9 | $410.3 | $75.7 | $24.2 | $654.1 | $164.3 | $818.3 |
| Leukemia | $145.2 | $469.6 | $118.2 | $25.7 | $758.7 | $131.8 | $890.5 |
| Lung | $401.4 | $416.2 | $490.0 | $45.4 | $1353.0 | $162.8 | $1515.8 |
| Melanoma | $103.2 | $540.1 | $43.1 | $24.2 | $710.6 | $394.1 | $1104.6 |
| Non-Hodgkin lymphoma | $390.2 | $611.5 | $147.7 | $38.1 | $1187.5 | $218.8 | $1406.3 |
| Oral cavity or pharynx | $171.3 | $161.8 | $78.9 | $18.1 | $430.0 | $109.8 | $539.9 |
| Ovary | $101.7 | $195.8 | $74.2 | $6.1 | $377.8 | $72.2 | $450.0 |
| Prostate | $805.2 | $1234.1 | $125.2 | $97.3 | $2261.8 | $1035.5 | $3297.3 |
| Thyroid | $138.3 | $499.7 | $11.8 | $12.6 | $662.4 | $265.5 | $927.8 |
| Corpus uterine | $171.0 | $256.8 | $47.8 | $17.6 | $493.2 | $231.2 | $724.5 |
| All sites combined | $4718.8 | $8878.2 | $2101.5 | $521.4 | $16219.9 | $4873.6 | $21093.6 |
National cancer prevalence estimates by age group, phase of care, and cancer site combined with annualized patient out-of-pocket costs from Surveillance, Epidemiology, and End Results Program-Medicare and annual patient time costs from the Medical Expenditure Panel Survey (MEPS).
Out-of-pocket costs estimated from patient responsibility for medical services (including infusion drugs) under Medicare Parts A/B claims. Out-of-pocket costs for oral prescription drugs estimated directly from Medicare Part D claims. Estimates from the MEPS in Table 5 were used to incorporate higher out-of-pocket spending in younger age group for medical services ($232.7 vs $97.7) and prescription drugs ($87.4 vs $67.0), yielding ratios of 2.38 and 1.30, respectively. All estimates are in 2019 US dollars.